Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study
Topless et al.,
Gout and the risk of COVID-19 diagnosis and death in the UK Biobank: a population-based study,
The Lancet Rheumatology, doi:10.1016/S2665-9913(21)00401-X
UK Biobank retrospective showing a higher risk of COVID-19 cases and mortality for patients with gout. Among patients with gout, mortality risk was lower for those on colchicine, OR 1.06 [0.60-1.89], compared to those without colchicine, OR 1.38 [1.08-1.76].
risk of death, 23.2% lower, OR 0.77, p = 0.12, relative odds for patients with gout, model 2, RR approximated with OR.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Topless et al., 28 Jan 2022, retrospective, database analysis, United Kingdom, peer-reviewed, 6 authors, dosage not specified.
Abstract: Articles
Gout and the risk of COVID-19 diagnosis and death in the UK
Biobank: a population-based study
Ruth K Topless, Angelo Gaffo, Lisa K Stamp, Philip C Robinson, Nicola Dalbeth, Tony R Merriman
Summary
Lancet Rheumatol 2022;
4: e274–81
Published Online
January 28, 2022
https://doi.org/10.1016/
S2665-9913(21)00401-X
See Comment page e233
Biochemistry Department,
University of Otago, Dunedin,
New Zealand (R K Topless BSc,
Prof T R Merriman PhD);
Division of Clinical
Immunology and
Rheumatology, University of
Alabama at Birmingham,
Birmingham, AL, USA
(A Gaffo MD, Prof T R Merriman);
Birmingham Veteran Affairs
Medical Center, Birmingham,
AL, USA (A Gaffo); University of
Otago Christchurch,
Christchurch, New Zealand
(Prof L K Stamp PhD); University
of Queensland, Brisbane, QLD,
Australia (P C Robinson PhD);
Department of Medicine,
University of Auckland,
Auckland, New Zealand
(Prof N Dalbeth MD)
Correspondence to:
Prof Tony R Merriman, Division
of Clinical Immunology and
Rheumatology, University of
Alabama at Birmingham,
Birmingham, AL 35233, USA
tony.merriman@otago.ac.nz
Background There is a paucity of data on outcomes for people with gout and COVID-19. We aimed to assess whether
gout is a risk factor for diagnosis of COVID-19 and COVID-19-related death, and to test for sex- and drug-specific
differences in risk.
Methods We used data from the UK Biobank, which included 15 871 people with gout. We used multivariable-adjusted
logistic regression in the following analyses using a case-control study design: to test for an association between gout
and COVID-19 diagnosis in the entire UK Biobank cohort (n=459 837); to test for an association between gout and
COVID-19-related death in people who were known to have died or survived with COVID-19 (n=15 772); to test for an
association between gout and COVID-19-related death in the entire UK Biobank cohort (n=459 837); and to assess risk
of COVID-19-related death in a subset of patients from the UK Biobank cohort with prescription data, stratified by
prescription of urate-lowering therapy and colchicine (n=341 398). Models 1 and 2 were adjusted for age group, sex,
ethnicity, Townsend deprivation index, BMI, and smoking status. Model 2 was also adjusted for diagnosis of 16 other
diseases that are established comorbidities of gout or established risk factors for COVID-19-related death.
Findings Gout was associated with diagnosis of COVID-19 (odds ratio [OR] 1·20, 95% CI 1·11–1·29) but not with risk
of COVID-19-related death in the cohort of patients diagnosed with COVID-19 (1·20, 0·96–1·51). In the entire cohort,
gout was associated with COVID-19-related death (1·29, 1·06–1·56); women with gout had an increased risk of
COVID-19-related death (1·98, 1·34–2·94), whereas men with gout did not (1·16, 0·93–1·45). We found no significant
differences in the risk of COVID-19-related death according to prescription of urate-lowering therapy or colchicine.
When patients with gout were stratified by vaccination status, the risk of diagnosis with COVID-19 was significant in
the non-vaccinated group (1·21, 1·11–1·30) but not the vaccinated group (1·09, 0·65–1·85).
Interpretation Gout is a risk factor for COVID-19-related death in the UK Biobank cohort, with an increased risk in
women with gout, which was driven by risk factors independent of the metabolic comorbidities of gout.
Funding Health Research Council of New Zealand.
Copyright © 2022 Elsevier Ltd. All rights reserved.
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit